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Abstract
Results of thrombolysis by monotherapy with either tPA or proUK have not lived up to ex-
pectations. Since these natural activators are inherently complementary, this property can
be utilized to a synergistic advantage; and yet, this has undergone little evaluation. ProUK
is no longer available because at pharmacological concentrations it converts to UK in plas-
ma. Therefore, a single site proUK mutant, M5, was developed to address this problem and
was used in this study. Fibrinolysis was measured using preformed fluoresceinated 24 h old
clots in a plasma milieu rather than by the standard automated method, because proUK/M5
is sensitive to inactivation by thrombin and activation by plasmin. The shortest 50% clot
lysis time that could be achieved by tPA or M5 alone was determined: mean times were 55
and 48 minutes respectively. These bench marks were matched by 6% of the tPA mono-
therapy dose combined with 40% that of M5: mean lysis time 47 minutes with less associat-
ed fibrinogenolysis. Results showed that the tPA effect was limited to initiating fibrinolysis
which was completed by M5 and then tcM5. Plasma C1-inhibitor inhibited fibrinogenolysis
by M5, providing protection from side effects not available for proUK. In conclusion, by utiliz-
ing the complementary properties and sequential modes of action of each activator, more
efficient fibrinolysis with less non-specific effects can be achieved than with traditional
monotherapy. In vivo validation is needed, but in a previous clinical trial using a similar com-
bination of tPA and proUK (5% and 50%monotherapy doses) very promising results have
already been obtained.
Introduction
Thrombolysis with tPA is the current standard for this therapeutic modality. After important
successes in acute myocardial infarction (AMI), tPA has since been replaced by percutaneous
coronary intervention (PCI) as the treatment of choice, despite PCI being much more time-
consuming and costly. Two problems may have contributed to this outcome. First, tPA’s thera-
peutic efficacy was compromised by a dose-limiting incidence of intracranial hemorrhage
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(ICH) [1]. Second, there was a relatively high coronary rethrombosis rate with tPA [2, 3] asso-
ciated with hematological evidence of thrombin generation [4–6].
In ischemic stroke, a further dose reduction was required due to a 20% incidence of ICH
when tPA doses equivalent to those in AMI were used [7], and reocclusion rates of 14–31%
were reported [8–10]. In a national estimate of use, only 2–5% of patients with ischemic
stroke were treated with tPA in the US [11], though the percentage is higher in dedicated
stroke centers.
These limitations of therapeutic thrombolysis reflect the experience with tPA thrombolytic
monotherapy. In contrast to monotherapy, certain previous studies showed that tPA may be
more effective when combined with the other natural plasminogen activator, prourokinase
(proUK), due to a synergistic combined effect [12, 13], although others did not find this syner-
gism [14]. The mechanism responsible for synergy has also been described [15], but proUK is
no longer available. The proUK mutant, M5, has the same mechanism of action so should also
be synergistic with tPA, but this has not, heretofore, been established.
Certain potentially useful clinical properties of proUK were established during its clinical
trials, including phase III trials in AMI [16–18]. For example, proUK induced little (5%) [17]
or no [19] rethrombosis and did not induce a procoagulant effect in blood [19] in contrast to
tPA. Unfortunately, at therapeutic concentrations in plasma, the intrinsic activity of proUK
[20] was sufficient to induce systemic plasmin generation, resulting in systemic conversion of
proUK to urokinase (UK) and consequent loss of fibrin-specificity. As a result of the bleeding
hazard from this, marketing approval for proUK was denied by the European Medicines Agen-
cy (EMEA). In order to address this problem, a more stable mutant proUK, designated M5,
was developed and was used in the present study.
M5 is a single site mutant (Lysine 300!Histidine) of proUK with a lower single-chain in-
trinsic activity [21] but with the same two-chain M5 (tcM5) activity as UK [22], and its fibrino-
lytic mode of action did not differ from that of proUK. In a thromboembolic model in dogs,
M5 thrombolysis was associated with significantly less bleeding than that by native proUK or
tPA [23]. This was found to be due to an unusual inhibition of tcM5 by C1-inhibitor in plasma
[24], an effect that could be augmented by adding pharmaceutical C1-inhibitor which inhibited
fibrinogenolysis but not fibrinolysis by M5 [25, 26].
In the present study, the fibrinolytic and fibrinogenolytic effects of tPA or M5 alone, at
doses which induced the shortest lysis time achievable, were compared with those of fractional
combinations. Standardized clots in a plasma milieu were used in the fibrinolytic assay, since
the standard, automated assay was precluded for use with proUK/M5 due to its sensitivity to
thrombin and plasmin, which respectively inactivate and activate the proenzyme. The findings
showed that a synergistic fractional dose combination induced optimal lysis times with fewer
non-specific effects, which could be further attenuated by C1-inhibitor. The results suggest
that combination thrombolytic therapy is more effective, safer, and more rational than mono-
therapy with either activator alone.
Methods and Materials
Materials
Mutant proUK (M5) from E coli was prepared by PxTherapeutics (Grenoble, France). Single-
chain tissue plasminogen activator (tPA) (CathFlo) was obtained from Genentech (South San
Francisco, CA). Fibrinogen was human, Kabi Grade L (Chromogenix, Milan, Italy). Aprotinin
and fluorescein isothiocyanate were from Sigma Chemicals, St. Louis, MO. Thrombin (Throm-
boMax, 100 NIH U per ml) was obtained from Sigma (St Louis, MO). C1-inhibitor was clinical
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grade from CSL Behring, Marburg, Germany. Human outdated bank plasma, pooled from four
donors, was used.
Methods
Explanation of Methodology.. Studies of fibrinolysis by proUK cannot use the automated
clotting/lysis assay which has become standard for other activators. When this is used with
proUK, thrombin inactivates some of the proUK at the outset, and whatever proUK remains
will then be converted quickly to UK during the lytic phase by plasmin. As a result, the stan-
dard assay measures the fibrinolytic activity of the remaining UK, a non-specific activator, but
not that of proUK. Therefore, a 24 h old preformed clot was used in a plasma milieu. A plasma
milieu is essential, not only to approximate in vivo lysis, but because in the absence of inhibi-
tors, the intrinsic activity of proUK/M5 activates plasminogen and plasmin then converts
proUK/M5 to UK/tcM5.
In previous studies of fibrinolysis with proUK using this clot lysis model, the results ob-
tained correlated well with those later found in clinical studies. For example, conversion of
proUK to UK above a certain concentration in plasma was seen during clot lysis in vitro and in
the clinical trials; synergy was identified first in this model in vitro and then found in vivo; and
even the plasma concentration of proUK required for effective clot lysis in this model (1.5 μg/
ml) and that used clinically (2–3 μg/ml steady state concentration) were similar. Since proUK
is a very species-specific activator, the in vitro results in human plasma often correlated better
with clinical findings than those from animal models.
Clot Lysis Experiments.. Clots were made up from 0.2 ml pooled blood bank plasma by
recalcification (35 mM) with the addition of a trace of thromboplastin and a tracer of fluores-
ceinated fibrinogen [27]. The clots were first incubated at 37°C for 1 hour and then overnight
at room temperature. The following day, the clots were placed into 2 ml of pooled bank plasma
and the activators added as specified. Clot lysis was monitored by taking 50 μl samples at time
points for reading of fluorescence, representing fibrin degradation products released from
the clots.
The lysis curves were plotted as percent lysis over time. The 100% point was obtained from
the mean of the highest readings at complete lysis. The base line reading was obtained at onset,
since the plasma shows fluorescence (~15% of the full signal) which was subtracted to obtain
the zero point. The time to 50% lysis under each of the experimental conditions was deter-
mined from the lysis graphs and was used as the principal endpoint.
Each clot lysis experiment was done in triplicate. Graph Pad Prism was used for preparing
graphs and for statistical analysis (means and Standard Deviation).
Fibrinogen determination.. After clot lysis had gone to completion, a final plasma sample
(1.0 ml) was obtained for determination of fibrinogen. Further proteolysis was prevented by
the addition of aprotinin (200 KIU/ml) to the sample. The results were recorded as percent of
the baseline (BL) fibrinogen obtained from a plasma sample before addition of the activators.
Fibrinogen was measured as thrombin-clottable protein. After dilution of the plasma sample
with 1 vol. phosphate-buffered saline, thrombin (200 μl of 1,000 NIH units/ml) was added,
mixed gently, and incubated for 1 hour at 37°C, and then overnight at room temp. The follow-
ing morning, each clot was wound onto a thin, long stemmed plastic transfer pipette tip to
which the gel adhered, and the serum content was expressed by pressure against the test tube
wall and then against a paper towel. The white-appearing fibrin on the pipette stem was then
placed in>5ml saline for>1h to allow diffusion of any remaining serum proteins. Then the fi-
brin was peeled off the tip and placed into 1 ml of 5% NaOH, boiled for 1 min, and then kept at
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room temp until all fibrin had gone into solution. The protein in the solution was measured
spectrophotometrically at 280 nm.
Experimental Plan and Conditions.. The shortest time to lysis obtainable by the activa-
tors alone and the fibrinogen that remained at the end of lysis were first determined. This was
done by incremental increases of dosing of the activators until no further shortening of the
lysis time occurred. This lysis time served as the benchmark against which various combina-
tions of tPA and M5 were compared, in order to select the combination which induced a com-
parable effect. Once a combination was selected, the contributions to lysis of the components
separately were determined from the results. Evaluation of the effect of C1-inhibitor on fibrino-
lysis and fibrinogenolysis was also determined.
a) Determination of the shortest time to lysis and fibrinogenolysis for tPA and M5 alone: The
shortest time was defined as that at which no further dose-dependent shortening of the lysis
time could be induced. The corresponding dose was called the maximum dose. The time to
50% clot lysis was determined from the lysis curves for tPA and M5.
b) The effect of C1-inhibitor on fibrinogenolysis: C1-inhibitor (750 μg/ml) was added to the
plasma prior to clot lysis by M5 at the three highest doses. In studies with the low-dose combi-
nation, the C1-inhibitor was added 30 minutes after the activators, since previous studies
showed that C1-inhibitor inhibits tPA-mediated fibrinolysis [28].
c) Determining a fractional combination of tPA and M5 that induces a time to 50% lysis com-
parable to maximum-dose monotherapy: Lysis by numerous combinations and ratios of tPA
and M5 were tested. The criterion for selection was the lowest dose of each activator that in
combination with the other induced a 50% lysis time comparable to the monotherapy bench-
mark. Fibrinogen remaining in plasma was determined at the end of lysis.
In some experiments, the effect of C1-inhibitor (750 μg/ml) on fibrinogenolysis and fibrino-
lysis was tested.
d) The effect on lysis of a range of doses of tPA in combination with selected M5 dose in the
fractional combination: The effect of increasing tPA doses from 0.2 to 3 μg/ml (the maximum
dose) in combination with M5 (6 μg/ml) was tested. The purpose of this experiment was to de-
termine if tPA had a lytic effect beyond that of the lowest dose which was required for the initi-
ation of fibrinolysis.
e) The mean lysis times and SD obtained in all experiments under the different conditions
were calculated and presented together in a bar graph.
f) The hematological effect of the synergistic combination of tPA and M5 when incubated
(37°C) in plasma alone without a clot was determined. Plasma samples were obtained hourly
for fibrinogen determination over a 5h period.
Results
Shortest 50% clot lysis time achievable by tPA or M5 alone
For tPA, an upper dose range of 1–3 μg/ml induced near to maximal lysis, and 3 μg/ml was the
maximum dose beyond which no further shortening of the lysis time was inducible. A repre-
sentative experiment with the top three doses is shown in which a 50% lysis time of 60 minutes
was found. The fibrinogen concentration at the end of lysis at each of these doses, expressed as
a percent of baseline, ranged from 19–45% of baseline and is shown in the bar graph below,
mean and SD values (Fig. 1A).
For M5, an upper dose range of 10–15 μg/ml induced near to maximal lysis, and 15 μg/ml
was the dose at which no further shortening of the lysis time was seen. A representative experi-
ment is shown in which the 50% lysis time was 50 minutes. The corresponding fibrinogen
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concentration at the end of lysis at the three doses ranged from 25–55% of baseline and is
shown in the bar graph below (Fig. 1B).
Effect of C1-inhibitor on fibrinogenolysis by M5
The experiment with the highest doses of M5 (10–15 μg/ml) was repeated in the presence of
supplemental C1-inhibitor (750 μg/ml) added to the plasma before the addition of M5. As
shown in Fig. 2 (top) this had no effect on the 50% clot lysis time which was 50 minutes. How-
ever, as shown in the bar graph (below), fibrinogen degradation was essentially prevented (1B).
The inhibition of M5-induced fibrinogenolysis but not fibrinolysis by this inhibitor was previ-
ously reported [25, 26].
The C1-inhibitor experiment was not repeated with tPA, since the C1-inhibition of fibrino-
genolysis by tPA was previously shown to be accompanied by comparable inhibition of fibrino-
lysis (28) as also seen in Fig. 3B (top) versus 3A (top).
Fig 1. Maximum dose lysis: Representative experiments showing clot lysis with fluorescein-labeled plasma clots by tPA (A) and M5 (B) using the three
highest doses up to the point at which no further shortening of the lysis time could be achieved. This represented the shortest lysis time achievable by each
activator alone, which was induced by 3 μg/ml tPA or 15 μg/ml M5. In the representative experiment shown, the shortest time to 50% lysis was 60 minutes for
tPA and 50 minutes for M5. In the bar graphs below, the fibrinogen concentrations at the end of clot lysis are shown, expressed as per cent of baseline (BL).
As much 80% of fibrinogen was lost to degradation.
doi:10.1371/journal.pone.0122018.g001
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Identification of a synergistic combination of tPA and M5
After multiple dose combinations of tPA and M5 were tested, the lowest dose of each activator
was chosen (0.2 μg/ml tPA and 6 μg/ml M5) which when used in combination induced a lysis
time equivalent to the shortest achievable with monotherapy. In some experiments even
0.1 μg/ml of tPA was sufficient to achieve this lysis time in combination with M5. These were
fractional concentrations consisting of 6% of the tPA and 40% of the M5 monotherapy dose
needed to induce a comparable lysis time, consistent with a synergistic effect. In the representa-
tive experiment shown, the 50% lysis time for the combination was 75 minutes, whereas it was
135 minutes for M5 (6 μg/ml) alone, indicating about a 45% shortening of the M5 lysis time by
the small dose of tPA. The lysis time by tPA alone at this dose (0.2 μg/ml) was 225 minutes
(Fig. 3A).
When the experiment was repeated with C1-inhibitor added 30 minutes after onset, fibrino-
genolysis was inhibited but not fibrinolysis by the combination. In fact the lysis time was short-
ened to 30 minutes, an effect that may have been related to conservation of M5 and
Fig 2. Effect of C1-inibitor: The experiment shown in Fig. 1B with M5 was repeated with prior addition of
C1-inhibitor (750 μg/ml) to the plasma. The lysis rate was not inhibited, in fact was shortened, fibrinogenolysis
was prevented. The experiment was not repeated with tPA because C1-inhibitor inhibits lysis by tPA (28) and
seen also in Fig. 3B.
doi:10.1371/journal.pone.0122018.g002
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plasminogen by the inhibitor. By contrast, fibrinolysis by the tPA alone was inhibited, as previ-
ously also found in vivo [28] (Fig. 3B).
Clot lysis by a fixed dose of M5 in combination with a range of tPA doses
The finding that tPA induced a major shortening of the M5 lysis time (Fig. 3) was consistent
with its function to initiate fibrinolysis by activating plasminogen on intact fibrin [33,34]. In
order to determine if tPA induced any additional lytic effect in presence of M5, a range of tPA
doses (0.2–3 μg/ml) was added to the fixed M5 dose of the combination (6 μg/ml). A 50% lysis
time of 48–60 minutes was found at all tPA doses without a discernible lytic effect beyond that
obtained with 0.2 μg/ml, consistent with its lytic effect being limited to that of the initiation of
fibrinolysis (Fig. 4).
Fig 3. The synergistic combination: (A) Representative clot lysis experiment using the synergistic combination (0.2 μg/ml tPA + 6 μg/ml M5) (circle), which
induced a 50% lysis time of 75 minutes. At this dose of M5 alone (triangle), the lysis time was 135 minutes, and tPA alone (square) induced a lysis time of 225
minutes. The findings show that a mini-dose tPA caused about a 45% shortening of the onset of lysis by M5. The plasma fibrinogens at the end of lysis
expressed as %BL fibrinogen are shown below. (B) The same experiment as above except that C1-inhibitor (750 μg/ml) was added 30 minutes after the
addition of the activators. As shown, this did not inhibit lysis, which was shortened to 30 minute, but did inhibit lysis by tPA alone. The C1-inhibitor attenuated
fibrinogenolysis, as shown below.
doi:10.1371/journal.pone.0122018.g003
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Mean and range of all the 50% clot lysis times
The minutes (mean and SD) of the 50% clot lysis times from all the experiments under the five
different conditions are shown. The number of experiments is in brackets. The synergistic com-
bination of 0.2 μg/ml tPA plus 6 μg/ml M5 induced an overall mean lysis rate of 47 [± 2.5] min-
utes; 0.2 μg/ml tPA alone was 156 [± 5.3] minutes; 6 μg/ml of M5 alone was 118 [± 7.2]
minutes; 15 μg/ml of M5 alone was 48 [± 1.6] minutes; and 3 μg/ml of tPA alone was 55 [± 5]
minutes. The shortest lysis time by the synergistic combination was lower than that by maxi-
mum dose tPA, but this difference did not reach significance (Fig. 5).
Fibrinogenolysis by the synergistic combination in the absence of a clot
Fibrinogen degradation in plasma by the synergistic combination (0.2 μg/ml tPA + 6 μg/ml
M5) alone over 2–5 h is shown (Fig. 6). There was no fibrinogen degradation seen for at least 3
h, which is a period well beyond the duration of therapeutic thrombolysis for stroke or AMI.
This finding also indicates that the plasminogen activation which was seen in the lysis experi-
ments by the combination was limited to that which was fibrin-dependent.
Discussion
There are two plasminogen activators in human plasma, tPA and proUK. They share a com-
mon substrate but are otherwise notably different in enzymatic nature, fibrin affinity, and
mode of action. Although therapeutic thrombolysis has invariably been by monotherapy, most
Fig 4. Lytic effect of range of tPA doses in presence of fixed low-dose M5: A representative experiment
in which clot lysis by the synergistic dose of M5 (6μg/ml) was combined with a range of doses of tPA, from the
synergistic dose (0.2 μg/ml) to the maximum lysis dose (3 μg/ml). No tPA lytic effect was detected beyond
that obtained with the lowest dose. The findings were consistent with the tPA lytic effect being confined to the
initiation of clot lysis.
doi:10.1371/journal.pone.0122018.g004
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 8 / 15
often with tPA, the natural system employs both activators to a synergistic advantage. This bio-
logical paradigm was investigated using a single-site mutant of proUK (designated M5) in
place of native proUK in a standardized model of clot lysis in a plasma milieu.
The shortest time to 50% clot lysis achievable by tPA or M5 alone was first determined and
became the benchmark against which the efficacy of different combinations of the activators
was compared. The respective shortest mean lysis times for tPA and M5 alone were 55 and 48
minutes and required 3 μg/ml and 15 μg/ml respectively. Extensive fibrinogenolysis accompa-
nied these doses (Fig. 1A & B), but with M5 this could be prevented by supplemental
C1-inhibitor without interfering with the rate of clot lysis (Fig. 2), whereas C1-inhibitor inhib-
ited fibrinolysis by tPA (Fig. 3B), as also found previously in an animal model [28]. These opti-
mally lytic doses of tPA are, of course, precluded clinically by ICH (1), especially in stroke
where a further dose reduction is needed [7].
After testing multiple dose combinations, a comparably short mean lysis time of 47 minutes
was induced by a fractional combination consisting of 6% of the tPA monotherapy dose
(0.2 μg/ml) and 40% of the M5 monotherapy dose (6 μg/ml) (Fig. 3, 5). Since this fractional
combination induced the same effect as the maximum achievable with monotherapy by either
activator, it was consistent with synergy, as previously observed with tPA and native proUK by
some investigators [12, 13] but not by others [14]. Fibrinogenolysis was less with the combina-
tion than with monotherapy and could be further attenuated by the addition of C1-inhibitor.
Although the C1-inhibitor inhibited lysis by tPA as shown (Fig. 3B), it maintained its synergis-
tic effect, indicating that tPA was present at some excess.
Fig 5. Lysis times from all the groups tested: The 50% lysis times (mean values and SD) from all the
experiments in the different groups: synergistic combination (47 ± 2.5); the low doses of tPA (156 ± 5.3) and
M5 (118 ± 7.2) in the synergistic combination when used alone; and the maximum doses of M5 (48 ± 1.6) and
tPA (55 ± 1.5). The number of experiments is shown in brackets above each bar; the numbers below the bars
are the μg/ml.
doi:10.1371/journal.pone.0122018.g005
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A similar combination of mini-dose tPA (5% of the standard dose) and low dose proUK
(50% standard hourly dose) was previously tested in vivo in a clinical study. In the multicenter
PATENT trial, 101 patients with AMI were treated [29]. The first 10 patients were treated with
a 10 mg bolus of tPA which turned out to be excessive, and the remainder with a 5 mg bolus;
each bolus was followed by a 40 mg per hour infusion of proUK for 90 minutes. A TIMI 2–3
coronary patency rate of 77% and a TIMI 3 patency rate of 60% were obtained, with no reoc-
clusions or ICH and only one death in the entire study. This patency rate was comparable to
that of full dose, front-loaded tPA in GUSTO [30], the study which led to the approval of tPA
for AMI [31].
The efficacy of a small amount of tPA seen in the present study as well as in the PATENT
trial, when in combination with proUK, reflects tPA’s biological role to initiate fibrinolysis.
In the event of a vascular occlusion, the tPA stored in the vessel wall is released locally, binds to
the clot, and initiates its degradation. The high fibrin affinity of tPA, mediated by both its finger
and kringle-2 domains [32], induces tight binding to a site on the D-domain of intact fibrin
[33] adjacent to plasminogen bound to lysine α157 [34]. The resulting ternary complex with fi-
brin promotes tPA plasminogen activation by about 1,000-fold [35]. Fibrinolysis is thereby ini-
tiated very efficiently, requiring little tPA as seen in Fig. 3A&B. Adding more tPA did not
change the lysis rate of the combination (Fig. 4) indicating that the tPA lytic effect was limited
to this first step.
ProUK/M5, by contrast, has no fibrin affinity and is a poor activator of plasminogen on in-
tact fibrin. Instead proUK/M5 requires some degradation of the fibrin surface for its specific fi-
brinolytic effect [15]. As a result, there is a lag phase that precedes clot lysis by M5 (Fig. 3) or
Fig 6. The effect of the synergistic dose combination in plasma alone: The synergistic combination of
the activators (0.2 μg/ml tPA and 6 μg/ml M5) was incubated (37°C) in plasma without a clot. No
fibrinogenolysis occurred for at least 3 h, showing that the plasminogen activation seen with the synergistic
combination was fibrin-dependent and no non-specific effect was detected by the synergistic combination.
doi:10.1371/journal.pone.0122018.g006
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proUK [15], which can be overcome by a high dose (Fig. 1B), but at this dose, fibrin specificity
is lost because of proUK conversion to the enzyme UK/tcM5 in plasma. After fibrin degrada-
tion is initiated by tPA, new plasminogen binding sites are created [36], including a high affini-
ty site on the fibrin E-domain [37]. When plasminogen binds to this site, it undergoes a
particular conformational change which makes it a favorable substrate for the proenzyme,
proUK/M5, itself. Against this conformation, the intrinsic activity of proUK is promoted more
than 250-fold, which gives it an activity equivalent to that of the enzyme, UK [38, 39], and a
similar phenomenon was observed when solid phase fibrin underwent degradation [40]. After
this plasminogen is activated by proUK; reciprocal activation of proUK by plasmin occurs [41]
during which proUK goes through a transitional hypercatalytic stage [42]. After UK/tcM5
forms, being a non-specific plasminogen activator, it can then activate the remaining fibrin-
bound plasminogen (Fig. 7).
During and after fibrinolysis, UK diffuses into the plasma where it activates plasma plasmin-
ogen which can induce side effects, since there is insufficient inhibitor in plasma for pharmaco-
logical UK concentrations. By contrast, tcM5 is effectively inhibited by C1-inhibitor which is
relatively plentiful in plasma (~250 μg/ml). Being an acute phase reactant, it is up-regulated in
Fig 7. Fibrinolysis by the sequential modes of action of tPA and proUK or M5: tPA binds (dashed line) to intact fibrin adjacent to plasminogen(Plg1),
forming a ternary complex and activation of Plg1 to plasmin (Plm). This initiates fibrin degradation resulting in the creation of new plasminogen binding sites
on fibrin. Plg2 binds to a high-affinity binding site on the fibrin E (FFE) domain, which induces a special conformational shape change in Plg2 that enables it to
be activated by the intrinsic activity of proUK. This proUK:plasminogen complex results in Plm formation and the reciprocal activation (double arrow) of
proUK!urokinase (UK), associated with a transitional state that is hypercatalytic. UK, being a non-specific enzyme, then activates the remaining fibrin-
bound plasminogen (Plg3). The three Plm together complete fibrin degradation (thick arrows) forming soluble fibrin degradation products (FDP). In the
Plasma Phase, when UK diffuses off the fibrin clot, if it is not inhibited, it will activate plasma Plg to Plm, resulting in the degradation of 3 clotting factors,
among other side effects. When M5 is used in place of proUK, this non-specific effect is prevented due to tcM5 being inhibited by C1INH, whose plasma
concentration is>1,000-fold greater than that of the UK inhibitor.
doi:10.1371/journal.pone.0122018.g007
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 11 / 15
disease states. C1-inhibitor is also available as a therapeutic agent. Since C1-inhibitor does not
inhibit fibrinolysis by M5 (Fig. 2 and 3B), it can be used as protection against non-specific effects
of fibrinolysis by M5 (Fig. 3B).
The contrasting properties of tPA and proUK/M5 account for their complementary effects
in fibrinolysis and make their utilization in a sequential combination for thrombolysis more ra-
tional than using either activator alone. The present findings indicate that a small amount of
tPA effectively initiates fibrinolysis which is then completed by proUK/M5 and UK/tcM5.
ProUK is no longer available, but M5 is a safer alternative that is similarly synergistic with tPA
as shown (Fig. 3A&B and Fig. 5).
The findings raise the question about the number of fibrin bound plasminogens available
for fibrinolysis. This question was investigated in a study in which the molar amounts of plas-
minogen on intact and degraded fibrin were measured [43]. The investigators found 23.4
nmol/l on intact fibrin and 61.9 nmol/l on degraded fibrin. Since intact fibrin has only a single
plasminogen binding site [33], these numbers are consistent with a total of three. Among
these, tPA activates the first one [34, 35], whereas M5 and tcM5 activated the other two on de-
graded fibrin [38, 40] (Fig. 7). The same proUK:tPA 2:1 ratio implicated by this was found in
a study in which the rates of fibrin-specific clot lysis (defined as <10% fibrinogen degrada-
tion) by tPA and by proUK in a plasma milieu were measured. The highest rate by proUK
was consistently twice that by tPA [44], corresponding to the ratio of plasminogen on
degraded and intact fibrin [43]. In the present study lysis by the M5 component in the syner-
gistic combination was also almost twice (lysis time about half as long) that of the tPA com-
ponent (Fig. 3A).
This additional fibrinolytic effect of proUK/M5 is a function of its activation to UK/tcM5
during fibrinolysis. When this was prevented by using an inactivatable proUK mutant, clot
lysis was diminished by 100-fold [45]. By contrast to proUK/M5, tPA undergoes no functional
change during fibrinolysis, since its single and two-chain forms have the same enzymatic and
fibrinolytic properties [46], consistent with tPA’s more limited function in fibrinolysis.
In conclusion, clot lysis in a plasma milieu by a combination of mini-dose tPA and
low-dose mutant proUK induced fibrinolysis of comparable efficacy to that by monotherapy
at maximum doses of either activator, doses which are precluded by side effects in therapeutic
thrombolysis with tPA [1]. The synergistic combination of tPA and M5 induced less
fibrinogenolysis, which was further attenuated by supplemental C1-inhibitor. M5 was
found to be synergistic with tPA as was proUK, and better suited for therapeutic use since
it was more stable in plasma and its non-specific effects were inhibited by plasma
C1-inhibitor (Fig. 7).
Acknowledgments
The authors thank Alexis Wallace for his valuable contributions to the writing of
the manuscript.
Author Contributions
Conceived and designed the experiments: VG RP. Performed the experiments: VG RP SL. Ana-
lyzed the data: RP VG. Wrote the paper: VG RP.
References
1. Gurwitz JH, Gore JM, Goldblerg RJ, Barron HV, Breen T, Rundle AC, et al. Risk for intracranial hemor-
rhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the
National Registry of myocardial infarction 2. Ann Intern Med 1998; 129: 597–604. PMID: 9786806
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 12 / 15
2. Verheugt FWA, Meijer A, LagrandWK, van Eenige MJ. Reocclusion: the flip side of coronary thrombol-
ysis. J Am Coll Cardiol 1996; 27: 766–773. PMID: 8613601
3. Gurewich V. Coronary rethrombosis after successful thrombolysis. An editorial comment. Circulation
1993; 87: 1759–1761. PMID: 8491032
4. Rapold HJ, Grimaudo V, Declerck PJ, Kruithof EK, Bachmann F. Plasma levels of plasminogen activa-
tor inhibitor type 1, β-thromboglobulin, and fibirnopeptide A before, during and after treatment of acute
myocardial infarction with alteplase. Blood 1991; 78: 1490–1495. PMID: 1832058
5. Gulba DC, Barthels M, Reil GH, Lichtlen PR. Thrombin/antihrombin-III complex level as early predictor
of reocclusion after successful thrombolysis. Lancet 1988; 2: 97. PMID: 2898712
6. Gulba DC, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel WG, et al. Increased thrombin
levels during thrombolytic therapy in acute myocardial infarction: relevance for the success of therapy.
Circulation 1991; 83: 937–944. PMID: 1900225
7. HackeW, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with
recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative
Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–1025. PMID: 7563451
8. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plas-
minogen activator. Neurology 2002; 59: 862–867. PMID: 12297567
9. Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early
arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
Stroke 2005; 36: 1452–1456. PMID: 15947260
10. Saqqur M, Molina CA, Salam A, Siddiqui M, Ribo M, Uchino K, et al. Clinical deterioration after intrave-
nous recombinant tissue plasminogen activator treatment: a multicenter transcranial doppler study.
Stroke 2007; 38: 69–74. PMID: 17138949
11. Kleindorfer D, Lindsell CJ, Brass I, Koroschetz W, Broderick JP. National US estimates of recombinant
tissue plasminogen activator use: ICD-9 codes substantially underestimates. Stroke 2008; 39:
924–928. doi: 10.1161/STROKEAHA.107.490375 PMID: 18239184
12. Gurewich V. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and
by tissue plasminogen activator. J Am Coll Cardiol 1987; 10: 16B–21B. PMID: 3117859
13. Gurewich V, Pannell R. Synergism of tissue-type plasminogen activator (t-PA) and single-chain uroki-
nase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb
Haemost 1987; 57: 372–378. PMID: 3116707
14. Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC. Absence of synergism between tissue-type
plasminogen activator (tPA), single-chain urokinase-type plasminogen activator (scuPA) and urokinase
on clot lysis in a plasmamilieu in vitro. Thrombosis Haemostasis 1986; 56: 35–39. PMID: 3095946
15. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator
(t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin
Invest 1988; 81: 853–859. PMID: 2963831
16. Michels R, Hoffmann H, Windeler J, Barth H, Hopkins G on behalf of the SUTAMI Investigators.
A double-blind multicenter comparison of the efficacy and safety of saruplase and urokinase in the
treatment of acute myocardial infarction: report of the SUTAMI Study Group. J Thromb Thrombolysis
1995; 2: 117–124. PMID: 10608014
17. PRIMI Trial Study Group. Randomised double-blind trial of recombinant pro-urokinase against strepto-
kinase in acute myocardial infarction. Lancet 1989; 1: 863–867. PMID: 2564949
18. Tebbe U, Michels R, Adgey J, Boland J, Caspi A, for The Comparison Trial of Saruplase and Streptoki-
nase (COMASS) Investigators. Randomized, double-blind study comparing saruplase with streptoki-
nase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998;
31: 487–493. PMID: 9502624
19. Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, Sasahara A, et al. New recombinant
glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol
1994; 241: 242–1248.
20. Pannell R, Gurewich V. The activation of plasminogen by single-chain urokinase or by two-chain
urokinase—a demonstration that single chain urokinase has a low catalytic activity (pro-urokinase).
Blood 1987; 69: 22–26. PMID: 3790724
21. Liu JN, TangW, Sun ZY, KungW, Pannell R, Sarmientos P, et al. A site-directed mutagenesis of pro-
urokinase which substantially reduces its intrinsic activity. Biochemistry 1996; 35: 14070–14076.
PMID: 8916892
22. Sun Z, Jiang Y, Ma Z, Wu H, Liu BF, Xu Y, et al. Identification of a flexible loop (297–313) of urokinase-
type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 1997; 272:
23818–23823. PMID: 9295329
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 13 / 15
23. Liu JN, Liu JX, Liu B, Sun Z, Zuo JL, Zhang J, et al. A prourokinase mutant which induces highly effec-
tive clot lysis without interfering with hemostasis. Circu Res 2002; 90: 757–763. PMID: 11964367
24. Gurewich V, Pannell R, Simmons-Byrd A, Sarmientos P, Liu JN, Badylak SF. Thrombolysis versus
bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
J Thrombos Haemost 2006; 4: 1559–1565. PMID: 16839354
25. Pannell R, KungW, Gurewich V. C1-inhibitor prevents non-specific plasminogen activation by a prouro-
kinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Haemost 2007; 5: 1047–1054.
PMID: 17459007
26. Gurewich V, Pannell R. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant
prouPA during optimal fibrinolysis. Thromb Haemost 2009; 102: 279–286. doi: 10.1160/TH08-09-0598
PMID: 19652878
27. Dmitry V, Sakharov J, Nagelkerke F, Dingeman C, Rijken DC. Rearrangements of the fibrin network
and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 1996; 271:
2133–2138. PMID: 8567670
28. Tomasi S, Sarmientos P, Giorda G, Gurewich V, Vercelli A. Mutant prourokinase with adjunctive C1-
inhibitor is an effective and safer alternative to tPA in rat stroke. PLos One. 2011; 6: e21999. doi: 10.
1371/journal.pone.0021999 PMID: 21779364
29. Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower J, Manzo K, et al. Sequential combina-
tion thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhance-
ment of thrombolysis (PATENT) trial. J Am Coll Cardiol 1995; 26: 374–379. PMID: 7608437
30. Rapaport E. GUSTO: Assessment of the preliminary results. J Myocard Ischemia 1993; 5: 15–24.
31. Topol E for the GUSTO Investigators. An international randomized trial comparing four thrombolytic
strategies for acute myocardial infarction. N Eng J Med 1993; 329: 673–682. PMID: 8204123
32. vanZonneveld AJ, Veerman H, Pannekoek H. On the interaction of the finger and the kringle-2 domain
of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by ε-amino ca-
proic acid. J Biol Chem 1986; 261: 14214–14218. PMID: 3021732
33. Yakovlev S, Makogonenko E, Kurochkina N, NieuwenhuizenW, Ingham K, Medved L. Conversion of fi-
brinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000;
39: 15730–15741. PMID: 11123898
34. Voskuilen M, Vermond A, VeenemanGH, van Boom JH, Klasen EA, Zegers ND, et al. Fibrinogen lysine
residue Aα157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, cata-
lyzed by tissue-type plasminogen activator. J Biol Chem 1987; 262: 5944–5946. PMID: 3106345
35. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue
plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912–2919. PMID: 7199524
36. Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding
of Glu-plasminogen to plasma fibrin I. Evidence for new binding site in plasmin-degraded fibrin I. J Biol
Chem 1985; 260: 4432 (abstr). PMID: 3156857
37. Varadi A, Patthy L. Beta (Leu121-Lys122) segment of fibrinogen is in a region essential for plasmino-
gen bonding by fibrin fragment E. Biochemistry 1984; 23: 2108–2112 (abstr). PMID: 6722138
38. Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-
plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (A-158-rpro-
UK). Biochemistry 1992; 31: 6311–6317. PMID: 1385727
39. Liu J, Gurewich V. A comparative study of the promotion of tissue plasminogen activator and pro-
urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 1991; 88:
2012–2017. PMID: 1836471
40. Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain
urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268:
18554–18559 PMID: 8103046
41. Petersen LC. Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template
formed by the urokinase receptor bound to poly (D-lysine). Eur J Biochem 1997; 245: 316–323. PMID:
9151959
42. Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase which has a higher catalytic efficien-
cy against glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289–15292. PMID: 1639775
43. Suenson E, Lützen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-
back mechanism in fibrinolysis. Eur J Biochem 1984; 140: 513–522. PMID: 6233145
44. Pannell R, Gurewich V. A comparison of the rates of clot lysis in a plasmamilieu induced by tissue plas-
minogen activator (t-PA) and rec-pro-urokinase: evidence that t-PA has a more restricted mode of ac-
tion. Fibrinolysis 1992; 6: 1–5.
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 14 / 15
45. Gurewich V, Pannell R, Broeze RJ, Jao JI. Characterization of the intrinsic fibrinolytic properties of pro-
urokinase through a study of plasmin resistant mutant forms produced by site specific mutagenesis of
lysine 158. J Clin Invest 1988; 82: 1956–1962. PMID: 2974047
46. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic
(tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920–2925. PMID: 7199525
Synergistic Thrombolysis with Mutant proUK and tPA
PLOSONE | DOI:10.1371/journal.pone.0122018 March 26, 2015 15 / 15
